I agree that good results are a positive thing. They increase the probability of the drug candidate’s success → the probability of future revenue increases. This is certainly a factor affecting the current stock price, but despite that, everything is still speculation. How much revenue would there be? For which diseases will the drug be used? Solid tumors? Market size? Faron’s share price naturally reacts to results and news in general, but the price development is news-dependent. Without news, the situation remains the same as after the previous news. And if you look at the big picture, the expectation (or actually the expectation) for Faron is a boolean value: whether the drug succeeds or not. In terms of returns, that single factor causes a price reaction between -100% ↔ +10,000%.
Nothing has necessarily failed if the price remains stagnant or even drifts down during quiet periods. It could be that an analyst has decided it’s time for a sell recommendation, and that lowers the price. Or Trump announces he intends to cut drug prices by 600%, in which case we would have to pay patients 5 times the price of the drug to take it. This has nothing to do with the development status or prospects of Faron’s drug candidate.
And I strongly believe that investors will be rewarded for holding Faron. It will happen at the latest when/if BEX successfully clears the trials. Then the returns you are looking for will come all at once.
We could, of course, get significant returns now through partnering, for example, but those returns would result from selling future revenues to a partner (Faron does not yet produce anything on its own). I believe that it is not the best way to preserve shareholder value, but I understand, of course, that a partner provides benefits beyond just funding. Still, I am a bit skeptical of selling future revenues at this stage, when a significantly low price is received for them due to uncertainty.